Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Entospletinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK known ✓ | P43405 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | ROS1 | P08922 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | CSNK2B | P67870 | 1/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 1/20 | 1.00 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Entospletinib SCHEMBL2483776 | 1.00 | SYK (1.00) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2481530 | 0.97 | SYK (1.00) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| Entospletinib SCHEMBL23777555 | 0.94 | SYK (0.89) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| Entospletinib SCHEMBL19283440 | 0.94 | SYK (0.89) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2893760 | 0.93 | SYK (0.87) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2480971 | 0.93 | SYK (0.87) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL3422119 | 0.92 | SYK (0.86) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2478771 | 0.92 | SYK (0.84) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2482901 | 0.91 | SYK (0.87) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2479102 | 0.91 | SYK (0.84) | SYKJAK2NTRK1ROS1CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 938 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090557-A1 | SYSTEMS AND METHODS FOR PROCESSING ISM AND MCAS CLINICAL TRIAL DATA | TELIOS PHARMA INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260097056-A1 | SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES | UNIV VIRGINIA PATENT FOUNDATION (US) | 2026-04-09 | — | — | US | claimed |
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250255889-A1 | METHODS FOR TREATMENT SELECTION FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | THE BROAD INSTITUTE, INC. (US) | 2025-08-14 | — | — | US | claimed |
| US-20250186432-A1 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION | 2025-06-12 | — | — | US | claimed |
| WO-2025052354-A1 | SYK INHIBITORS FOR USE IN THE TREATMENT OF IMMUNE CHECKPOINT INHIBITION INDUCED ADVERSE EVENTS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-03-13 | — | — | WO | claimed |
| EP-4520333-A1 | SYK INHIBITORS FOR USE IN THE TREATMENT OF IMMUNE CHECKPOINT INHIBITION INDUCED ADVERSE EVENTS | Albert-Ludwigs-Universität Freiburg (DE) | 2025-03-12 | — | — | EP | claimed |
| CN-119365194-A | Use of pyrazolopyridines for the treatment of BTK related diseases including central nervous system diseases | 成都嘉葆药银医药科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| US-20250025461-A1 | TREATMENT OF SEVERE AND UNCOMPLICATED MALARIA | NUREX S.R.L. (IT) | 2025-01-23 | — | — | US | claimed |
| EP-4493188-A2 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | Purdue Research Foundation (US) | 2025-01-22 | — | — | EP | claimed |
| CN-115605488-A | Bifunctional degradants of hematopoietic progenitor kinases and therapeutic uses thereof | 新锐思生物制药股份有限公司（US） | 2023-01-13 | — | — | CN | claimed |
| US-20220401436-A1 | METHODS FOR THE TREATMENT OF CANCERS THAT HAVE ACQUIRED RESISTANCE TO KINASE INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-12-22 | — | — | US | claimed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | claimed |
| EP-3625368-B1 | METHODS FOR ASSESSING THE RISK OF DEVELOPING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY CAUSED BY JOHN CUNNINGHAM VIRUS BY GENETIC TESTING | PML SCREENING LLC (US) | 2022-11-09 | — | — | EP | claimed |
| EP-4054579-A1 | METHODS FOR THE TREATMENT OF CANCERS THAT HAVE ACQUIRED RESISTANCE TO KINASE INHIBITORS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-09-14 | — | — | EP | claimed |
| EP-4055193-A1 | IRON-SCORE AND IN VITRO METHOD FOR IDENTIFYING HIGH RISK DLBCL SUBJECTS AND THERAPEUTIC USES AND METHODS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-09-14 | — | — | EP | claimed |
| US-20220241281-A1 | Imidazopyrimidine Derivatives | GILEAD SCIENCES, INC. | 2022-08-04 | — | — | US | claimed |
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | VALERIO THERAPEUTICS (FR) | 2022-05-12 | — | — | US | claimed |
| EP-3972695-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-03-30 | — | — | EP | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186432-A1 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | SYK, BTK, G6PD | SYK 1/4885JAK2 27/4885NTRK1 4175/4885 |
| US-20250255889-A1 | METHODS FOR TREATMENT SELECTION FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | BCL6B, BCL9, BCL9L | SYK 409/4885JAK2 202/4885NTRK1 3767/4885 |
| US-20220401436-A1 | METHODS FOR THE TREATMENT OF CANCERS THAT HAVE ACQUIRED RESISTANCE TO KINASE INHIBITORS | BRAF, FNTA, FNTB | SYK 2832/4885JAK2 418/4885NTRK1 266/4885 |
| US-20220241281-A1 | Imidazopyrimidine Derivatives | DPYD, KRAS, ABL1 | SYK 730/4885JAK2 15/4885NTRK1 4108/4885 |
| US-20260097056-A1 | SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES | SYK, BTK, FYN | SYK 1/4885JAK2 464/4885NTRK1 1271/4885 |
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | MAP3K20, MAP3K10, DCK | SYK 985/4885JAK2 395/4885NTRK1 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.